Equities research analysts expect Vaxart, Inc. (NASDAQ:VXRT) to announce $650,000.00 in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Vaxart’s earnings, with the highest sales estimate coming in at $800,000.00 and the lowest estimate coming in at $500,000.00. Vaxart posted sales of $520,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 25%. The company is scheduled to report its next earnings report on Thursday, August 5th.
According to Zacks, analysts expect that Vaxart will report full year sales of $3.72 million for the current financial year, with estimates ranging from $3.11 million to $4.34 million. For the next fiscal year, analysts expect that the company will report sales of $89.51 million, with estimates ranging from $37.65 million to $141.37 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that follow Vaxart.
Vaxart (NASDAQ:VXRT) last announced its quarterly earnings results on Sunday, May 2nd. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.04). The firm had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.62 million. Vaxart had a negative net margin of 2,844.24% and a negative return on equity of 39.81%. Vaxart’s revenue for the quarter was down 82.8% on a year-over-year basis.
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research upgraded Vaxart from a “sell” rating to a “hold” rating in a report on Wednesday, May 5th. B. Riley restated a “buy” rating and issued a $13.00 price target (down from $16.00) on shares of Vaxart in a research report on Thursday, March 4th.
In other news, Director Wouter Latour sold 100,000 shares of the stock in a transaction dated Friday, May 7th. The shares were sold at an average price of $7.13, for a total transaction of $713,000.00. Following the transaction, the director now owns 100,000 shares of the company’s stock, valued at approximately $713,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.30% of the stock is owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in VXRT. Nisa Investment Advisors LLC raised its holdings in shares of Vaxart by 398.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 14,900 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 11,912 shares during the last quarter. Heritage Wealth Advisors increased its stake in shares of Vaxart by 268.5% during the 4th quarter. Heritage Wealth Advisors now owns 9,950 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 7,250 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Vaxart during the 4th quarter worth approximately $89,000. Golden Green Inc. purchased a new stake in shares of Vaxart during the 4th quarter worth approximately $195,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Vaxart during the 4th quarter worth approximately $663,000. 30.00% of the stock is currently owned by institutional investors.
Shares of VXRT stock opened at $6.70 on Friday. The business has a fifty day simple moving average of $6.60 and a 200-day simple moving average of $7.01. Vaxart has a fifty-two week low of $2.23 and a fifty-two week high of $24.90. The stock has a market cap of $819.21 million, a P/E ratio of -14.26 and a beta of 0.27.
About Vaxart
Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection.
Further Reading: What is a blue-chip stock?
Get a free copy of the Zacks research report on Vaxart (VXRT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com